Immune Thrombocytopenia Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight's, "Immune Thrombocytopenia Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Immune Thrombocytopenia pipeline landscape. It covers the Immune Thrombocytopenia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Immune Thrombocytopenia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Immune Thrombocytopenia Pipeline. Dive into DelveInsight's comprehensive report today! @ Immune Thrombocytopenia Pipeline Outlook [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Immune Thrombocytopenia Pipeline Report

* On December 09, 2025 - Novartis reported positive findings from VAYHIT2, a Phase III trial evaluating ianalumab in combination with eltrombopag for patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids. The combination of ianalumab (9 mg/kg) plus eltrombopag prolonged ITP disease control by 45%, based on the primary endpoint of time to treatment failure (TTF), which reflects the duration patients maintain safe platelet levels during and following treatment. Median TTF for those receiving ianalumab plus eltrombopag reached 13.0 months-2.8 times longer than the 4.7 months observed with placebo plus eltrombopag.
* On December 09, 2025- Incyte Corporation conducted a phase 2A study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.
* On December 05, 2025- Novartis Pharmaceuticals conducted a study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count greater than or equal to 30 G/L in adult participants with primary ITP.
* On December 04, 2025- Eli Lilly and Company announced a study drug will be administered orally in participants with Primary Immune Thrombocytopenia (ITP). Blood tests will be performed to check how much pirtobrutinib gets into the bloodstream and how long it takes the body to eliminate it. The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo.
* On December 02, 2025- argenx initiated a study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV, respectively during the double-blinded treatment period (DBTP). At the end of the treatment period (up to 24 weeks), all participants will receive efgartigimod IV during the first 52-week open-label treatment period (OLTP1). At the end of the first OLTP1, participants may begin a second 52-week OLTP2. After the OLTP2, the participants will enter a follow-up period (approximately 8 weeks) while off study drug. The participants will be in the study for up to 138 weeks.
* DelveInsight's Immune Thrombocytopenia pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Immune Thrombocytopenia treatment.
* The leading Immune Thrombocytopenia Companies such as Corcept Therapeutics, UCB, arGEN-X, HanAll Biopharma/Immunovant, Momenta Pharmaceuticals, Principia Biopharma, Hutchison MediPharma, Cour Pharmaceutical Development and others.
* Promising Immune Thrombocytopenia Pipeline Therapies such as Huaiqihuang Granule, Avatrombopag, BT595, Romiplostim, Hetrombopag, Rilzabrutinib, SKI-O-703, Eltrombopag, TQB3473 Tablets, and others.

Stay ahead with the most recent pipeline outlook for Immune Thrombocytopenia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Immune Thrombocytopenia Treatment Drugs [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Immune Thrombocytopenia Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Immune Thrombocytopenia Pipeline Report also highlights the unmet needs with respect to the Immune Thrombocytopenia.

Immune Thrombocytopenia Overview

Immune thrombocytopenia (ITP), formerly known as Idiopathic thrombocytopenic purpura is an autoimmune bleeding disorder. The disease is characterized by abnormally low levels of blood cells called platelets. ITP manifests as a bleeding tendency, easy bruising (purpura), or extravasation of blood from capillaries into skin and mucous membranes (petechiae).

Immune Thrombocytopenia Emerging Drugs Profile

* Rozanolixizumab (UCB7665): UCB

Rozanolixizumab humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P). By blocking IgG recycling, this subcutaneously infused monoclonal antibody aims to improve the course of immunoglobulin G (IgG)-mediated autoimmune diseases by reducing pathogenic autoantibody levels. Rozanolixizumab, an investigational monoclonal antibody, was granted orphan drug designation for the treatment of ITP by the US Food and Drug Administration on 30 April 2018 and by the European Commission on 11 January 2019. The drug is in Phase III clinical studies for the treatment of idiopathic thrombocytopenic purpura, myasthenia gravis and in Phase II clinical studies for chronic inflammatory demyelinating polyradiculoneuropathy and encephalitis.

* Efgartigimod: arGEN-X

Efgartigimod is designed as a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn). Efgartigimod is being evaluated for the treatment of patients with severe autoimmune diseases with confirmed presence of pathogenic immunoglobulin G, IgG autoantibodies, where a severe unmet medical need exists. The drug is in registration phase for myasthenia gravis and in Phase III clinical studies for Primary Immune Thrombocytopenia (ITP), chronic inflammatory demyelinating polyradiculoneuropathy, and Pemphigus vulgaris.

Explore groundbreaking therapies and clinical trials in the Immune Thrombocytopenia Pipeline. Access DelveInsight's detailed report now! @ New Immune Thrombocytopenia Drugs [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Immune Thrombocytopenia Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Immune Thrombocytopenia with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Immune Thrombocytopenia Treatment.
* Immune Thrombocytopenia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Immune Thrombocytopenia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Immune Thrombocytopenia market

Immune Thrombocytopenia Companies

Corcept Therapeutics, UCB, arGEN-X, HanAll Biopharma/Immunovant, Momenta Pharmaceuticals, Principia Biopharma, Hutchison MediPharma, Cour Pharmaceutical Development and others.

Immune thrombocytopenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical

Immune Thrombocytopenia Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

Unveil the future of Immune Thrombocytopenia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Immune Thrombocytopenia Market Drivers and Barriers [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Immune Thrombocytopenia Pipeline Report

* Coverage- Global
* Immune Thrombocytopenia Companies- Corcept Therapeutics, UCB, arGEN-X, HanAll Biopharma/Immunovant, Momenta Pharmaceuticals, Principia Biopharma, Hutchison MediPharma, Cour Pharmaceutical Development and others.
* Immune Thrombocytopenia Pipeline Therapies- Huaiqihuang Granule, Avatrombopag, BT595, Romiplostim, Hetrombopag, Rilzabrutinib, SKI-O-703, Eltrombopag, TQB3473 Tablets, and others.
* Immune Thrombocytopenia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Immune Thrombocytopenia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Immune Thrombocytopenia Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Immune Thrombocytopenia Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Immune thrombocytopenia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Immune thrombocytopenia - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Rozanolixizumab (UCB7665): UCB
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Preclinical/Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Immune thrombocytopenia Key Companies
* Immune thrombocytopenia Key Products
* Immune thrombocytopenia- Unmet Needs
* Immune thrombocytopenia- Market Drivers and Barriers
* Immune thrombocytopenia- Future Perspectives and Conclusion
* Immune thrombocytopenia Analyst Views
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=immune-thrombocytopenia-clinical-trial-pipeline-accelerates-as-30-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.